<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821169</url>
  </required_header>
  <id_info>
    <org_study_id>2013_07</org_study_id>
    <secondary_id>2013-004410-17</secondary_id>
    <nct_id>NCT02821169</nct_id>
  </id_info>
  <brief_title>Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain</brief_title>
  <acronym>ROPI_POSTOP</acronym>
  <official_title>Impact of Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain in the Setting of Endoscopic Sinonasal Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic sinus surgery (ESS) is a prevalent surgical procedure. It is required in many
      chronic rhinosinusitis for whom the medical treatment failed. In order to improve the
      postoperative management of patients treated with ESS, we aim to assess the analgesic action
      of local injection of ropivacaine in the nasal fossa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized double blind placebo controlled study was designed. Local injection
      of ropivacaine or placebo was conducted at the end of the surgical procedure in both nasal
      fossa through endoscopic view in the sphenopalatine region.

      Pain was measured in the postoperative course with visual analogic scale in the recovery room
      and the rhinologic department.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale</measure>
    <time_frame>at the 2 postoperative hours</time_frame>
    <description>Measure the intensity pain, in the group treated with Ropivacaine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesics consumption orally</measure>
    <time_frame>during the 7 days post-surgery</time_frame>
    <description>patient-controlled administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale for the intensity postoperative pain</measure>
    <time_frame>at the 4 and at the 6 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale for the during postoperative pain</measure>
    <time_frame>At Morning and evening between the 1 and 7 days post surgery</time_frame>
    <description>self-assessment by the patient at home on the information collection book</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>saline solution 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>injection of saline solution in the sphenopalatine area in both nasal fossa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ropivacaine (2mg/ml)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of ropivacaine in the sphenopalatine area in both nasal fossa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <description>injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach</description>
    <arm_group_label>ropivacaine (2mg/ml)</arm_group_label>
    <other_name>NAROPEINE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution 0.9%</intervention_name>
    <description>injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach</description>
    <arm_group_label>saline solution 0.9%</arm_group_label>
    <other_name>NaCL 0.9% injectable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients requiring endoscopic sinus surgery

          -  ASA score 1 or 2

          -  patients with health care insurance

          -  approved consent

        Exclusion Criteria:

          -  any sinonasal malignant tumor

          -  renal failure, hepatic disorder, respiratory deficiency, cardiovascular diseases

          -  neurologic disorders

          -  alcohol or drugs addiction

          -  preoperative facial pain from an extranasal origin

          -  coagulation disorders

          -  antidepressive treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goeffrey Mortuaire, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Goeffrey Mortuaire, MD,PhD</last_name>
    <email>geoffrey.mortuaire@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU, HÃ´pital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Mortuaire, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sinus surgery</keyword>
  <keyword>sphenopalatin ganglion</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>local anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Ganglion Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

